Correspondence 0001104659-23-054339 from AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963) (ATXI)
AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963)
Date: May 1, 2023 · CIK: 0001644963 · Accession: 0001104659-23-054339
AI Filing Summary & Sentiment
File numbers found in text: 333-271208
Show Raw Text
CORRESP
1
filename1.htm
Avenue Therapeutics, Inc.
1111 Kane Concourse, Suite 301, Bay Harbor
Islands, FL 33154
VIA EDGAR
May 1, 2023
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Alan Campbell
Re: Avenue Therapeutics, Inc.
Registration Statement
on Form S-1 (File. No. 333-271208)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 under
the Securities Act of 1933, as amended, Avenue Therapeutics, Inc. (the “Company”) hereby requests that the Securities
and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement
on Form S-1 (as amended, the “Registration Statement”) so that the Registration Statement will be declared effective
as of 4:30 p.m. Eastern time, on May 3, 2023, or at such other time as the Company or its outside counsel, McGuireWoods LLP, may request
via a telephone call to the staff of the Commission.
Once the Registration Statement
has been declared effective, please orally confirm that event with David Wolpa of McGuireWoods at (704) 343-2185, or in his absence, Rakesh
Gopalan of McGuireWoods LLP at (704) 343-2275.
Thank you for your assistance
in this matter.
Sincerely,
Avenue Therapeutics, Inc.
/s/ Alexandra MacLean
Alexandra MacLean, Chief
Executive Officer